Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Roberto FerraraMarie NaigeonEdouard AuclinBoris DuchemannLydie CassardJean-Mehdi JouniauxLisa BoselliJonathan GrivelAude DesnoyerLaura MezquitaMatthieu TexierCaroline CaramellaLizza E L HendriksDavid PlanchardJordi RemonSabina SangalettiClaudia ProtoMarina C GarassinoJean-Charles SoriaAurélien MarabelleAnne-Laure VoisinSiham FarhaneBenjamin BesseNathalie ChaputPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Circulating T-cell immunosenescence is observed in up to 28% of patients with aNSCLC and correlates with lack of benefit from ICI but not from PCT.See related commentary by Salas-Benito et al., p. 374.